The REP has been used effectively for screening in several neurodegenerative disease pathways including Alzheimer's disease (tau and Aβ), Parkinson's disease, polyglutamine diseases (poly Q and ataxin-1), and motor neuron disease (Lenz et al., 2013; Shulman et al., 2014; Hannan et al., 2016). This evidence concerns the gene MAPT and Parkinson disease.